← Back to Search

Monoclonal Antibodies

LY3819469 for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline up to week 49
Awards & highlights

Study Summary

This trial is testing a new drug to see if it's safe and effective in reducing high levels of Lp(a), a type of cholesterol. The study will last up to 53 weeks for participants in Part A, and 29 weeks for participants in Part B.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline up to week 49
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline up to week 49 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Secondary outcome measures
PK: Maximum Observed Drug Concentration (Cmax) of LY3819469
Pharmacodynamics (PD): Change From Baseline in Fasting Lp(a)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC[0-∞]) of LY3819469

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: LY3819469 (Part B)Experimental Treatment1 Intervention
Single doses of LY3819469 administered SC in Japanese Participants.
Group II: LY3819469 (Part A)Experimental Treatment1 Intervention
Single ascending doses of LY3819469 administered subcutaneously (SC).
Group III: Placebo (Part B)Placebo Group1 Intervention
Placebo administered SC.
Group IV: Placebo (Part A)Placebo Group1 Intervention
Placebo administered SC.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3819469
2023
Completed Phase 1
~120

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,618 Previous Clinical Trials
3,201,451 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,347 Previous Clinical Trials
405,645 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study of LY3819469 in Healthy Participants
2021. "A Study of LY3819469 in Healthy Participants". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04914546.
~17 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top